Characteristics | N = 56 (%) |
---|---|
Age | |
 Median years (range) | 72 (48–85) |
Gender | |
 Male/female | 37 (66) / 19 (34) |
Performance status | |
 0 / 1 / 2 | 24(43) / 28 (50) / 4 (7) |
Smoking status | |
 Current / Former / Never | 20(36) / 25(45) / 11 (20) |
Histology | |
 Adeno / Sq / Non-small | 25(45) / 30(54) / 1(2) |
Primary tumor location | |
 Upper lobe or trachea / Middle or lower lobe | 33(59) / 23 (41) |
Clinical stage | |
 |||A/|||B/|||C/Others | 19(34) /14(25) /10(18) /13 (23) |
PD-L1 Satus | |
 ≥ 50% /1–49% / < 1% / unknown | 9(16) /11(20) / 19(24) / 17(30) |
Irradiation technique | |
 IMRT | 28 (50) |
 3D-CRT | 28 (50) |
Total radiotherapy dose | |
 60 Gy/30fr | 48 (86) |
 66 Gy/33fr | 5 (9) |
 54 Gy/27fr | 1 (2) |
 50 Gy/25fr | 2 (4) |
Chemotherapy regimen | |
 wCBDCA + PTX | 26 (46) |
 CDDP + VNR | 12 (21) |
 CDDP + Pemetrexed | 12 (21) |
 CDDP + S-1 | 6 (11) |
Pulmonary function test | |
 Median %VC (range) | 89.0 (53.5–124.4) |
 Median %FEV1.0 (range) | 80.6 (46–126) |